Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
M.N. Acar Tayyar , M.Ö. Tamam , G.B. Babacan , M.C. Şahin , H. Özçevik , S. Şengiz Erhan , A.E. Öztürk
{"title":"Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos","authors":"M.N. Acar Tayyar ,&nbsp;M.Ö. Tamam ,&nbsp;G.B. Babacan ,&nbsp;M.C. Şahin ,&nbsp;H. Özçevik ,&nbsp;S. Şengiz Erhan ,&nbsp;A.E. Öztürk","doi":"10.1016/j.remn.2024.500080","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [<sup>18</sup>F]FDG PET/CT and to investigate its impact on survival.</div></div><div><h3>Methods</h3><div>Pretreatment metabolic parameters measured by [<sup>18</sup>F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.</div></div><div><h3>Results</h3><div>Among the 117 patients, 17.1% were HER2-positive (HER2<sup>+</sup>), and 82.9% were HER2-negative (HER2<sup>−</sup>). There was no significant association between PET/CT parameters in the HER2<sup>+</sup> and HER2<sup>−</sup> patient groups. HER2<sup>+</sup> patients had higher 1- and 3-year survival expectations than HER2<sup>−</sup> patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.</div></div><div><h3>Conclusion</h3><div>This study showed no association between HER2 expression and [<sup>18</sup>F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500080"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Medicina Nuclear E Imagen Molecular","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253654X24001136","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [18F]FDG PET/CT and to investigate its impact on survival.

Methods

Pretreatment metabolic parameters measured by [18F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.

Results

Among the 117 patients, 17.1% were HER2-positive (HER2+), and 82.9% were HER2-negative (HER2). There was no significant association between PET/CT parameters in the HER2+ and HER2 patient groups. HER2+ patients had higher 1- and 3-year survival expectations than HER2 patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.

Conclusion

This study showed no association between HER2 expression and [18F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.
通过[18F]FDG PET/TC预处理胃腺癌的病理数据获得的HER2状态与代谢参数之间的关系
目的人表皮生长因子受体2 (HER2)过表达被认为在胃癌中更具侵袭性。本研究旨在利用[18F]FDG PET/CT评估HER2状态和其他预后病理参数的可预测性,并探讨其对生存的影响。方法回顾性评估117例her2分析患者的治疗前代谢参数[18F]FDG PET/CT作为预后因素。检查病理资料、肿瘤代谢特征与远处转移的关系,并探讨对生存的影响。结果117例患者中,HER2阳性(HER2+)占17.1%,HER2阴性(HER2−)占82.9%。HER2+和HER2 -患者组PET/CT参数之间无显著相关性。HER2+患者的1年和3年生存率预期高于HER2 -患者(80-37.9%;47.5 - -20%;分别)。两组总生存率无统计学差异。cox -回归分析中,血管浸润、局部浸润和远处转移是不良预后因素,HER2不是预后因素。血管侵犯和局部侵犯(T3/T4)也与较高的SUVmax值相关。远处转移患者的SUVmax、SUVmean和TLG显著升高。结论本研究显示HER2表达与[18F]FDG PET/CT代谢参数无相关性。然而,无论HER2状态如何,结果表明远处转移、局部侵袭和血管侵袭可能与原发性肿瘤代谢有关。PET/CT参数预测肿瘤侵袭性和疾病预后优于HER2状态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Espanola De Medicina Nuclear E Imagen Molecular
Revista Espanola De Medicina Nuclear E Imagen Molecular RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
1.10
自引率
16.70%
发文量
85
审稿时长
24 days
期刊介绍: The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信